Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

P2RY2 fuelled by eATP drives cancer immune evasion and therapy resistance

ABSTRACT: In this study, we identify P2RY2 as a pivotal upstream driver of both PGE2 accumulation and B7-H3 upregulation in the TME. This process is fuelled by extracellular ATP (eATP), a cognate ligand for P2RY2 that is commonly and markedly elevated in the TME and rises further under immunotherapies. Genetic or pharmacological disruption of P2RY2 substantially reduces intratumoural PGE2 and B7-H3, increasing T cell infiltration, effector functions, proliferation, and persistence within the TME. Consequently, targeting P2RY2 substantially improves the efficacy of TCR-engineered T cells, CAR-T cells, and immune checkpoint blockade (ICB) in multiple syngeneic and humanized mouse tumour models, and potentiates patient-derived tumour-infiltrating lymphocytes (TILs) against paired primary tumour cells. By establishing P2RY2 as the crucial link between eATP and tumour-induced immunosuppression, our study reveals how a receptor typically associated with innate “danger” signalling can be hijacked to undermine adaptive immunity, thereby providing a promising therapeutic avenue to overcome a common immune resistance mechanism in cancer and advance T cell–based cancer therapies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE289055 | GEO | 2026/07/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

P2RY2 fuelled by eATP drives cancer immune evasion and therapy resistance

Project description:P2RY2 fuelled by eATP drives cancer immune evasion and therapy resistance

| PRJNA1220715 | ENA

A Clinical Trial of TAA06 Injection in Advanced Solid Tumors

Project description:B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn’t express on normal tissues. Therefore, B7-H3 is an ideal target for chimeric antigen receptor (CAR) T cells therapy. TAA06 injection is a CAR T injection targeting B7-H3. This is a phase I clinical study with the primary objective of evaluating the safety and tolerability of TAA06 injection in subjects with TAA06-positive advanced solid tumors. The secondary objectives are as follows: to evaluate the distribution, proliferation and persistence of B7-H3-targeted CAR T cells after injection of TAA06 in subjects; to preliminarily evaluate the efficacy of TAA06 injection in subjects with TAA06-positive advanced solid tumor.

| 2400863 | ecrin-mdr-crc

Identification of the B7-H3 Interaction Partners Using a Proximity Labeling Strategy

Project description:B7-H3 has emerged as a promising target for cancer therapy due to its high expression in various types of cancer cells. It not only regulates the activity of immune cells but also modulates the signal transduction and metabolism of cancer cells. However, the specific interaction partners of B7-H3 still remain ambiguous, limiting a comprehensive understanding of the precise role of B7-H3 in cancer progression. In this study, we reported that B7-H3 can bind to resting Raji cells, stimulated THP-1 cells, and even PC3 prostate cancer cells through its IgV domain alone. Furthermore, to identify the potential interaction partners of B7-H3 on these cells, we adopted an APEX2-based proximity labeling strategy, which unveiled about 10 key potential interaction partners. Interestingly, our results suggested that CD45 could be a putative receptor for B7-H3 on Raji cells, while EGFR could closely interact with B7-H3 on PC3 cells. Based on further computational structure modeling studies, we showed that B7-H3 can bind to the EGF binding pocket of EGFR, surprisingly stronger than EGF itself. Overall, our study provides an effective approach to identifying B7-H3 interaction partners in both immune and cancer cell lines.

2024-12-23 | PXD059197 |

Unveiling Transcriptional Mechanisms of B7-H3 in Breast Cancer Stem Cells Through Proteomic Approaches

Project description:B7-H3, an immune checkpoint molecule, is overexpressed in various solid cancers, correlating with negative prognosis and poor clinical outcomes. However, its regulatory mechanisms in aggressive cancers and cancer stem cells (CSCs), which contribute to cancer formation, progression, chemoresistance, and recurrence, remain unclear. To elucidate the mechanisms regulating B7-H3 expression in breast CSCs, we employed DNA affinity purification-mass spectrometry (DAP-MS) with presumptive promoter regions of B7-H3 and identified several proteins binding to that promoter regions in CSC specific manner. Subsequent validation studies identified several potential transcription factors, including DNA damage-binding protein 1 (DDB1), XRCC5, PARP1, RPA1, and RPA3, for their significant impact on B7-H3 expression. In vitro inhibition of DDB1 with its known inhibitor, nitazoxanide, resulted in a marked decrease in B7-H3 expression, suppressing tumor sphere formation and cell migration in breast CSCs. Our findings reveal a transcription factor-mediated regulatory mechanism for B7-H3 in CSCs through proteomic analysis and highlight the critical role of these transcription factors in regulating B7-H3 expression. These results may elucidate underlying mechanisms, paving the way for the development of new immunotherapeutic strategies against breast cancer.

2025-05-07 | PXD054584 | Pride

Co-IP interactome studies of FRS2/B7-H3 ± C7/Chloroquine in UW228 cells

Project description:Fibroblast growth factor receptor substrate 2 (FRS2) and B7-H3/CD276 are both highly expressed in medulloblastoma (MB) patient samples. While FRS2 has been shown to drive an invasive tumor phenotype, the biological role of B7-H3/CD276 is still incompeletely understood. Here, we explored the interactome of FRS2 and B7-H3/CD276 in MB cells stimulated with bFGF. Further, we studied the treatment impact with the FRS2 small molecule ligand C7 on both interactomes, as well as the effect of chloroquine on the interactome of B7-H3/CD276. Towards this aim, we expressed mNeonGreen-tagged FRS2 and B7-H3/CD276 in UW228 cells and isolated direct interactor proteins via pulldown using mNeonGreen-trap magnetic agarose beads. We performed mass spectrometry and quantified relative abundances compared to pulldowns from wild type UW228 cells.

2026-09-07 | PXD062611 | Pride

LC-ESI-MS/MS on a purified recombinant protein sample to confirm its amino acid sequence and a certain cleavage site

Project description:The study entails the design, production and in vitro testing of a novel recombinant anti-B7-H3 affibody coupled with a small cytotoxic protein, with considerable potential in Acute Myeloid Leukemia (AML) immunotherapy. The protein construct was expressed in E. coli. After affinity purification and validation of its sequence through LC-MS/MS, the obtained protein’s efficacy was tested on AML representative B7-H3-positive THP-1 cells and B7-H3-negative RAJI cells. The IC50 of the cytotoxic protein was determined through MTS assay and its apoptotic and necrotic activities on the two cell lines were evaluated through flow cytometry and Western blot. Taken together, the results show that the cytotoxic anti-B7-H3 affibody we produced possesses highly necrotic and apoptotic targeted effects that are specific to only B7-H3-expressing THP-1 cells and not the RAJI control line. Moreover, these observed effects are significantly more potent than the effects of the cytotoxin alone, as they are described in previous studies. In conclusion, we designed, produced and evaluated a novel anti-B7-H3 cytotoxic affibody that from these preliminary in vitro data, shows high potential for translation to the immunotherapy of AML.

2025-10-24 | PXD065453 | Pride

B7-H3 interactome in HaCaT cells by IP/MS

Project description:Immunoprecipitation coupled with mass spectrometry (IP/MS) was performed in HaCaT cells using an anti-B7-H3 antibody to identify B7-H3-interacting proteins. Raw mass spectrometry data are provided.

| PXD078471 |

Targeting Osteosarcoma with Canine B7-H3 CAR T Cells and Impact of CXCR2 Co-Expression on Functional Activity

Project description:Abstract. The use of large animal spontaneous models of solid cancers, such as dogs with osteosarcoma (OS), can help develop new cancer immunotherapy approaches, including chimeric antigen receptor (CAR) T cells. Therefore, the goal of the present study was to generate canine CAR T cells targeting the B7-H3 (CD276) co-stimulatory molecule overexpressed by several solid cancers, including OS and glioma in both humans and dogs, and to assess their ability to recognize B7-H3 expressed by canine OS cell lines or by canine tumors in xenograft models. A second objective was to determine whether a novel dual CAR that expressed a chemokine receptor together with the B7-H3 CAR improved the activity of the canine CAR T cells. Therefore, in the studies reported here we examined B7-H3 expression by canine OS tumors, evaluated target engagement by canine B7-H3 CAR T cells in vitro, and compared the relative effectiveness of B7-H3 CAR T cells versus B7-H3-CXCR2 dual CAR T cells in canine xenograft models. We found that most canine OS tumors expressed high levels of B7-H3, whereas levels were undetectable on normal dog tissues. In vitro, both B7-H3 CAR T cells demonstrated activation and OS-specific target killing in vitro, but there was significantly greater cytokine production by B7-H3-CXCR2 CAR T cells. In canine OS xenograft models, little antitumor activity was generated by B7-H3 CAR T cells, whereas B7-H3-CXCR2 CAR T cells significantly inhibited tumor growth, inducing complete tumor elimination in most treated mice. These findings indicated therefore that addition of a chemokine receptor could significantly improve the anti-tumor activity of canine B7-H3 CAR T cells, and that evaluation of this new dual CAR construct in dogs with primary or metastatic OS is warranted since such studies could provide a critical and realistic validation of the chemokine receptor concept.

2024-04-03 | GSE247355 | GEO

RNA sequencing analysis for mouse ovarian cancer cells and tumors response to B7-H3 (Cd276) depletion

Project description:Analysis of mouse ovarian cancer cell lines HM-1 and ID8, and HM-1 tumors inoculated to B6C3F1 mice with B7-H3 (Cd276) knockout (KO) by CRISPR-Cas9. We identified B7-H3 expression is upregulated in IFN-γ–low, PD-L1–low non-immunoreactive tumors of high grade serous ovarian cancer. We explored the influence of B7-H3 on immune evasion outside of its direct regulatory function on target cells by generating B7-H3 knockout cell lines and tumors in syngeneic mouse models.

2022-01-10 | GSE174137 | GEO

Gene Expression Based Characterization of B7H3 In Prostate Cancer [BCR]

Project description:B7-H3 (CD276), part of the B7 superfamily, has been shown to play an immunomodulatory role, however its regulation, receptor, and mechanism of action remain unclear. Protein levels of B7-H3 have been previously shown to relate to prostate cancer outcomes and currently, humanized monoclonal antibodies are being investigated for clinical therapeutic use (enoblituzumab, MGA271, Macrogenics). Here we use genomic expression data to examine the relationship of B7-H3 to prostate cancer clinical characteristics and molecular profile.

2016-05-12 | GSE79956 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data